Xinovi announced that the company's application for an initial public offering of shares and listing on the Science and Technology Innovation Board has been reviewed and approved by the Shanghai Stock Exchange Listing Committee and approved for registration by the China Securities Regulatory Commission. The current public offering of 653,33.52 million A-shares, accounting for 15% of the total number of shares after issuance. The issue price was 27.60 yuan/share. The total capital raised was 1,803 billion yuan, and the net amount was 1,683 billion yuan, which will be used for new drug research and development projects and supplementary working capital. The offering uses a combination of strategic placement, offline inquiry placement, and online pricing distribution. The sponsor's relevant subsidiaries, company executives, and core employees participated in the strategic placement, and the corresponding allotted shares were limited to 24 months and 12 to 36 months, respectively.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.